MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Zymeworks Inc. (NASDAQ: ZYME)*
Organization & Developments: Zymeworks
Parents
Zymeworks Inc. (NASDAQ: ZYME)*
Children
*ChromaDex
*Preclinical-stage biopharma focused on protein-based therapeutics for oncology and inflammatory disease
2014: Zymeworks Nabs $15M, Adds Lilly Partnership, in Antibody Drug Quest (2014)
2020: Zymeworks: Oncology Drug Discovery Company With Major Big Pharma Deals
2022 Zymeworks Inc. 2022 Q3 - Results - Earnings Call Presentation_seekingalpha.com
2022: Bloodletting at Zymeworks as new CEO axes half of senior leaders, plans 25% reduction in headcount
2022: Zymeworks wanted a Big Pharma partner for its bispecific. Jazz Pharmaceuticals said OK
2022: Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone_ seekingalpha.com
2023: Jiving with Jazz after $325M opt-in, Zymeworks links HER2 bispecific to 84% survival after 18 months
2023: Revisiting Zymeworks After A Big Licensing Deal_seekingalpha.com
2023: Zymeworks: Good Data, Lots Of Cash, Stagnant Stock_ seekingalpha.com
2023: Zymeworks' Robust Financials And The Potential Biotech Resurgence (NASDAQ:ZYME)
2023:Zymeworks: Late-Stage Study Data In 2024 Makes This A Must-Watch_ seekingalpha.com
2024: Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data_
2024: Unlocking the potential of antibody drug conjugates
2024: Zymeworks Approaching A Moment Of Truth With Zanidatamab
2024: Zymeworks Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
2024: Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion
2024: Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule
2024: Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind
2024: Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab
2024: Zymeworks’ Future Hinges on Developing Key Diagnostic Tests Amidst Regulatory Challenges
2024:Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year
2025: 3 Biotech Stocks With Notable Insider Buying
2025: Zymeworks Advances New Treatment
2025: Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On
2025: Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)
2025: Zymeworks: Its Post-Approval Future
2026: A Post Acquisition Look At Zymeworks
Jumps
*Key People: Zymeworks
Finance & Acquisitions: Zymeworks